Precigen, Inc. (NASDAQ:PGEN) Shares Bought by LexAurum Advisors LLC

LexAurum Advisors LLC grew its holdings in Precigen, Inc. (NASDAQ:PGEN) by 151.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 691,544 shares of the biotechnology company’s stock after buying an additional 417,055 shares during the quarter. LexAurum Advisors LLC’s holdings in Precigen were worth $775,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. SG Americas Securities LLC boosted its holdings in Precigen by 27.9% during the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after buying an additional 12,578 shares in the last quarter. Synovus Financial Corp lifted its position in shares of Precigen by 100.0% during the 3rd quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 49,065 shares during the period. Barclays PLC boosted its stake in shares of Precigen by 190.4% during the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 124,141 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after acquiring an additional 149,829 shares during the period. Finally, State Street Corp increased its stake in Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after purchasing an additional 29,253 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Stock Performance

PGEN stock opened at $1.34 on Friday. The stock’s 50 day moving average price is $0.93 and its 200 day moving average price is $1.06. The firm has a market cap of $392.44 million, a P/E ratio of -2.44 and a beta of 1.65. Precigen, Inc. has a 1 year low of $0.65 and a 1 year high of $1.93.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $6.00 target price (up from $4.00) on shares of Precigen in a research report on Thursday. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, Precigen currently has an average rating of “Hold” and an average price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.